| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Oncology | ||
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Oncology | ||
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
UroGen Pharma Ltd.$38.56
-1.67 (-4.15%)
C 40Pipeline Score Overvalued Biotech · Commercial
Market Cap
1.41 B
EPS
-2.76
P/E Ratio
-
Value Trade
12.99 M
SEC Financials
Q1 2026Dilution Risk
Revenue
50.96 M
R&D Expenses
15.60 M
Operating CF
-45.32 M
Total Assets
253.69 M
Total Liabilities
377.94 M
Equity
-124.25 M
D/E Ratio
12,345
-1.26 %
Week
13.38 %
1 Month
34.37 %
3 Month
16.87 %
6 Month
53.1 %
5 Year
117.55 %
All Time
Cash Data
Cash Position
149.71 M
Monthly Burn
15.11 M
Runway
8 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
1.28 M
52 Week Range
3.61 - 32.37
% held by Insiders
20.95 %
% held by Institutions
87.61 %
Enterprise Value
1.46 B
Total Shares
48.71 M
Short %
13.68 %
Float Shares
45.44 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for UroGen Pharma Ltd.
303Total events
9Upcoming
93Tier-1 (high impact)
2016 – 2031Coverage
Upcoming catalysts 9
Jun 30, 2027
T2Debt Royalty Financing
Second tranche of $50M available at Company's discretion until June 30, 2027
Event history 294
Q3 2026
●NDA SubmissionUGN-103Regulatory Filing
NDA submission for UGN-103 expected in Q3 2026
recurrent low-grade intermediate-risk non-muscle invasive bladder cancersource ↗
Jun 10, 2026
◆Oral PresentationPresentation
UroGen management to present at Goldman Sachs 47th Annual Global Healthcare Conference
Jun 2, 2026
▲IP Litigation RulingJELMYTOApprovedIP / Competition
Settlement and license agreement with Teva resolving patent litigation for JELMYTO
low-grade Upper Tract Urothelial Cancer (LG-UTUC)source ↗
Jun 2026
◆Full ResultsUGN-103Clinical Data
Six-month durability data for UGN-103 expected in mid-2026
recurrent LG-IR-NMIBCsource ↗
May 19, 2026
May 17, 2026
●Oral PresentationZUSDURIApprovedPresentation
KOL panel on real-world experience with ZUSDURI at AUA annual meeting
recurrent LG-IR-NMIBCsource ↗
May 15, 2026
▲Topline ReadoutUGN-103Clinical Data
UGN-103 achieved 94.5% six-month DOR in Phase 3 UTOPIA trial
recurrent low-grade intermediate-risk non-muscle invasive bladder cancersource ↗
May 15, 2026
▲Patent GrantedUGN-103IP / Competition
U.S. patents covering RTGel with medac's mitomycin formulation and use in LG-IR-NMIBC; protection to December 2041
recurrent low-grade intermediate-risk non-muscle invasive bladder cancersource ↗
May 13, 2026
▲Full ResultsZUSDURIApprovedClinical Data
36-month DOR of 64.5% by KM estimate; median DOR not reached at median follow-up of 35.5 months
recurrent low-grade intermediate-risk non-muscle invasive bladder cancersource ↗
Drug Pipeline Intelligence
C40
Pipeline Score $517M
Pipeline ValueOvervalued
Valuation Signal6
Drugs Scored0.4x
rNPV / MCap Top 57%
Micro Cap (rank 393 of 911)
Percentile RankUroGen Pharma Ltd. carries a moderate pipeline score (40/100), with $1.8B risk-adjusted pipeline value, led by UGN-101 instillations in Carcinoma, Transitional Cell (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UGN-101 instillations Small molecule | Carcinoma, Transitional Cell | Phase 3 | NCT02793128 | 42% | $871M | COMPLETED | 71 | - | - | Mar 5, 2020 | - | Dec 22, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ZUSDURI | recurrent low-grade intermediate-risk non-muscle invasive bladder cancer | Phase 3 | 2026-05-13 | 64.5%; 95% CI, 54.6% - 72.8%; 79.6%; 35.5 months | ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial Read More | |
ZUSDURI | recurrent low-grade intermediate-risk non-muscle invasive bladder cancer | Phase 3 | 2026-05-13 | 64.5%; 95% CI, 54.6% - 72.8%; 79.6%; 35.5 months | ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial Read More | |
ZUSDURI | recurrent low-grade intermediate-risk non-muscle invasive bladder cancer | Phase 3 | 2026-05-13 | 64.5%; 95% CI, 54.6% - 72.8%; 79.6%; 35.5 months | ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in URGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
URGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
URGNUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. has announced the grant of inducement restricted stock units (RSUs) to 21 new employees to support the commercialization of its products JELMYTO® and ZUSDURITM. The RSUs, which can amount to up to 102,700 ordinary shares, will vest over three years. This initiative is aligned with Nasdaq Listing Rule 5635(c)(4) and reflects UroGen's commitment to enhancing its workforce as they continue to develop their cancer treatment pipeline.
Read more →URGNUroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
UroGen Pharma has entered into a settlement agreement with Teva Pharmaceuticals, resolving patent litigation regarding the generic version of JELMYTO. Under the agreement, Teva will be allowed to sell its generic version starting September 15, 2030, pending FDA approval. This resolution highlights UroGen's strong intellectual property portfolio and its commitment to advancing treatments for urothelial cancers.
Read more →URGNUroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
UroGen Pharma Ltd. will present at the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026. The presentation will be available via webcast on the company's website. UroGen specializes in treatments for urothelial and specialty cancers, utilizing its proprietary RTGel technology for sustained drug release.
Read more →URGNUroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
UroGen Pharma has reported promising results from its Phase 3 UTOPIA trial, showing a 94.5% durability of response for UGN-103 in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The data aligns closely with the outcomes from the pivotal ENVISION trial of ZUSDURI, which is significant for the FDA approval pathway. UroGen plans to submit a New Drug Application for UGN-103 by Q3 2026, highlighting its potential to become a new standard of care in uro-oncology. The innovative treatment aims to enhance patient outcomes through improved delivery methods.
Read more →URGNZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
UroGen Pharma announced promising results from the Phase 3 ENVISION trial of ZUSDURI for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The trial showed a 64.5% probability of remaining disease-free at three years for patients achieving a complete response at three months. Notably, these durable outcomes were achieved without the need for maintenance therapy, highlighting ZUSDURI's potential to transform treatment approaches.
Read more →URGNUroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma Ltd. has announced its participation in several upcoming investor conferences in May 2026. The events will take place at different locations, including Las Vegas and New York, with one conference being held virtually. The company intends to engage with investors through one-on-one meetings, providing insights into its innovative solutions designed to treat urothelial and specialty cancers.
Read more →URGN▲ +10.2%on this news· ran to +31% by day 3shared move
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
UroGen Pharma reported significant financial growth in Q1 2026, with ZUSDURI generating $29.2 million in revenue, a 109% increase from the previous quarter. The company also highlighted advancements in its pipeline, including plans for an NDA submission for UGN-103 later this year. Despite the positive revenue growth, UroGen recorded a net loss of $23.6 million during the quarter.
Read more →URGNUroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
UroGen Pharma Ltd. announced it will report its financial results for the first quarter of 2026 on May 6th, 2026, before the stock market opens. A subsequent audio webcast and conference call will take place at 10:00 AM Eastern Time. Investors will have access to a live stream and a replay for approximately 30 days. This event underscores UroGen's ongoing activities in the biotech sector.
Read more →URGN▲ +5.9%on this news
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma Ltd. has launched the "LG-UTUC Luminaries" initiative to honor clinicians and institutions making significant impacts in the treatment of low-grade upper tract urothelial cancer (LG-UTUC). This initiative aims to advance kidney-sparing care and improve patient outcomes by recognizing excellence in clinical practice. The first honoree is Dr. Saum Ghodoussipour from Rutgers Cancer Institute, acknowledged for his leadership in LG-UTUC care. The initiative emphasizes collaboration and ongoing education in the urology community to further support those affected by this rare cancer.
Read more →URGNJournal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Pharma announced the publication of the Phase 3 ENVISION trial results for ZUSDURI, showing a 72.2% probability of remaining event-free at 24 months after achieving a complete response. The trial results, published in The Journal of Urology, highlight ZUSDURI's potential to significantly improve the management of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The treatment offers a non-surgical option for patients, marking a significant advancement in bladder cancer therapy.
Read more →URGNUroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
UroGen Pharma Ltd. praised the Bladder Cancer Advocacy Network (BCAN) for its New Faces of Bladder Cancer Report, which highlights the fears and procedural burdens faced by bladder cancer patients. The report reveals that nearly 80% of respondents experience fear of recurrence, with numbers rising significantly in younger patients. It also documents the high number of cystoscopies patients endure, emphasizing the chronic nature of bladder cancer. UroGen's support for the research reflects its commitment to improving care through patient-centric data.
Read more →URGNUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2026
UroGen Pharma Ltd. has announced the grant of inducement restricted stock units (RSUs) to 11 new employees as part of their employment. This move aims to support the commercialization of their approved products, JELMYTO® and ZUSDUR™, and the development of their pipeline. The RSUs will vest over three years, contingent on the employees' continued service.
Read more →URGN▼ -12.4%on this news
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
UroGen Pharma announced the successful commercial launch of ZUSDURI, the first FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, achieving $15.8 million in net sales for 2025. The company also reported a net loss of $153.5 million for the year, while advancing its pipeline with promising results from ongoing trials for UGN-103 and UGN-104. The permanent J Code for ZUSDURI, effective January 1, 2026, is expected to enhance reimbursement and patient access.
Read more →URGN▼ -12.4%on this newsshared move
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
UroGen Pharma has announced a refinancing agreement with Pharmakon Advisors, securing a senior secured term loan of up to $250 million. The first tranche of $200 million will refinance existing debt and provide additional capital, while a second tranche of $50 million is available until June 30, 2027. The agreement aims to lower UroGen's cost of capital and enhance its financial position.
Read more →URGNZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
UroGen Pharma announced promising results from the Phase 3 ENVISION trial of ZUSDURI, showing durable complete response rates in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The drug demonstrated high efficacy across EORTC recurrence score groups, with significant numbers of patients remaining recurrence-free at 24 months. These findings will be presented at the upcoming ASCO-GU 2026 conference.
Read more →URGNUroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
UroGen Pharma Ltd. will present at the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026. The company focuses on developing innovative treatments for urothelial and specialty cancers. UroGen's products include a proprietary hydrogel technology aimed at enhancing drug delivery and effectiveness. A webcast of the presentation will be available on their corporate website.
Read more →URGNUroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
UroGen Pharma Ltd. will report its fourth quarter and full-year 2025 financial results on March 2, 2026. The announcement will be made before the stock market opens, followed by a live audio webcast and conference call. UroGen specializes in developing treatments for urothelial and specialty cancers, with notable FDA-approved products.
Read more →URGNUroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
UroGen Pharma Ltd. will present at the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11-12, 2026. The conference will be accessible via webcast on UroGen's corporate website. UroGen focuses on innovative solutions for urothelial and specialty cancers, with products approved for treating specific cancer types.
Read more →URGNPermanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
UroGen Pharma announced that a permanent J Code for ZUSDURI (mitomycin) is now effective, enhancing access for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The new code, J9282, simplifies billing and reimbursement, aiming to reduce delays in treatment. This development is expected to significantly benefit patients and healthcare providers alike.
Read more →URGNUroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
UroGen Pharma Ltd. will present at the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. The company focuses on developing innovative treatments for urothelial and specialty cancers, including its proprietary RTGel technology. Webcasts of the presentation will be accessible on their Investor Relations website for 90 days following the event.
Read more →URGN▲ +21.9%on this news
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
UroGen Pharma reported its Q3 2025 financial results, highlighting the successful launch of ZUSDURI, the first FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Despite slower-than-expected patient starts, the company noted strong demand and engagement from urologists. Financially, UroGen achieved $27.5 million in total revenue, with ZUSDURI contributing $1.8 million in its initial quarter.
Read more →URGN▲ +21.9%on this newsshared move
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
UroGen Pharma announced a 77.8% three-month complete response rate from its Phase 3 UTOPIA trial for UGN-103, aimed at treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The FDA has agreed that results from this trial can support a New Drug Application submission for UGN-103. This represents a key regulatory milestone for UroGen as it positions UGN-103 as a potential growth driver.
Read more →URGNUroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
UroGen Pharma Ltd. will present at the Guggenheim Securities Healthcare Innovation Conference from November 10-12, 2025. The company focuses on developing innovative treatments for urothelial and specialty cancers, including FDA-approved therapies for bladder cancer. Webcasts of the conference will be available for investors and interested parties.
Read more →URGNUroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
UroGen Pharma Ltd. will announce its third quarter 2025 financial results on November 6, 2025, before the market opens. Following the announcement, a live audio webcast and conference call will be held at 10:00 AM ET. UroGen specializes in developing treatments for urothelial and specialty cancers, with innovative drug delivery technologies.
Read more →URGN▲ +9.9%on this newsshared move
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
UroGen Pharma announced that the Centers for Medicare and Medicaid Services has assigned a permanent J Code, J9282, for ZUSDURI, effective January 1, 2026. This coding is expected to streamline billing and reimbursement processes for healthcare providers, facilitating better access to this FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The J Code represents a significant operational milestone for UroGen as it prepares for the launch of ZUSDURI.
Read more →URGNZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
UroGen Pharma has published a review highlighting the clinical development of ZUSDURI, the first FDA-approved treatment for recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer. The review emphasizes ZUSDURI's durable efficacy and manageable safety profile, making it a viable outpatient treatment option. The clinical program includes three late-phase trials demonstrating significant results.
Read more →URGN▼ -7.1%on this news
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
UroGen Pharma announced the launch of ZUSDURI, an FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The company reported a net loss of $49.9 million for Q2 2025, an increase from the previous year. Despite the losses, UroGen's revenue from JELMYTO grew by 11%, reflecting strong demand. The company is optimistic about its pipeline and market opportunities.
Read more →URGNUroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma announced a 24-month duration of response of 72.2% from the Phase 3 ENVISION trial of ZUSDURI, the first FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. This significant result highlights the sustained efficacy of ZUSDURI, providing a new outpatient treatment option that may reduce the need for repeated surgeries. The trial involved 240 patients and demonstrated the potential for durable complete responses.
Read more →URGNUroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
UroGen Pharma has announced that it will report its financial results for the second quarter of 2025 on August 7th, prior to market opening. Following this announcement, a live audio webcast and conference call will take place at 10:00 AM ET. This event will provide investors with insights into the company's financial performance and strategic direction in oncology.
Read more →URGNUroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology
UroGen Pharma announced the publication of results from a Phase 3b study in Reviews in Urology, showcasing the feasibility of home instillation of ZUSDURI for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The results indicated that home health professionals can safely administer ZUSDURI, with a 75% completion rate among patients and significant patient satisfaction. The study, however, faced limitations such as a small sample size and an open-label design, which may affect the robustness of its conclusions.
Read more →URGNUROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit
UroGen Pharma is currently facing a class action lawsuit related to its product UGN-102, which is intended to treat non-muscle invasive bladder cancer. The lawsuit arises from allegations that the ENVISION clinical trial was inadequately designed, lacking a control arm, and failing to address FDA concerns. Following negative feedback from the FDA and an unfavorable advisory committee vote, UroGen's stock experienced significant drops. Investors are urged to evaluate their rights in the ongoing lawsuit with the final deadline for participation set for July 28, 2025.
Read more →URGNUroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma has published findings from a five-year extension study of the Phase 2b OPTIMA II trial, revealing that ZUSDURI, an intravesical treatment for low-grade intermediate-risk non-muscle invasive bladder cancer, provides durable responses. Patients who achieved complete response (CR) exhibited a median duration of response of 3.5 years. The data highlights ZUSDURI's potential as a non-surgical treatment option, valuable for recurrent patients who typically face repeated surgeries. Safety data were not collected during the long-term follow-up trial, indicating areas for further research.
Read more →URGNUROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit
A class action lawsuit has been filed against UroGen Pharma Ltd. (URGN) in the U.S. District Court for the District of New Jersey, alleging false and misleading statements regarding the clinical efficacy of their product, UGN-102. The lawsuit claims that UroGen's study design lacked a necessary control arm, leading to difficulties in demonstrating drug effectiveness. Additionally, the FDA had previously highlighted concerns about this study design. Following a negative advisory committee vote, UroGen's stock price dropped significantly, raising concerns among investors.
Read more →URGNUROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in UroGen Pharma (URGN) to Inquire About Their Rights in Class Action Lawsuit
Bragar Eagel & Squire, P.C. announces a class action lawsuit against UroGen Pharma for alleged misleading statements regarding the clinical study of their product UGN-102. The lawsuit claims that the study design was flawed, failing to meet FDA recommendations for a concurrent control arm, which puts UroGen's new drug application at risk. The FDA has expressed concerns over the efficacy results from the ENVISION study, leading to sharp declines in UroGen's stock price following negative feedback. Investors who suffered losses are being encouraged to contact the law firm for potential legal action.
Read more →URGNUROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd. And Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against UroGen Pharma Ltd. on behalf of investors who acquired UroGen securities between July 27, 2023, and May 15, 2025. The lawsuit alleges that UroGen made false statements regarding the efficacy of its drug UGN-102, which is intended for the treatment of bladder cancer. Significant concerns have been raised by the FDA about the clinical study design for UGN-102, which lacks a control group, leading to questions about its effectiveness. Following unfavorable FDA feedback, UroGen's stock price has significantly decreased, prompting investor action.
Read more →URGNUroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. has completed patient enrollment for the Phase 3 UTOPIA clinical trial of UGN-103, targeting recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The trial enrolled a total of 99 patients across multiple centers and aims to evaluate the efficacy and safety of UGN-103, which utilizes UroGen's proprietary RTGel technology. This innovative formulation seeks to streamline treatment processes compared to existing solutions. The primary endpoint will focus on the complete response rate after three months of treatment.
Read more →URGN▲ +19.2%on this news
UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds UroGen Pharma Ltd. Investors of Upcoming Deadline
UroGen Pharma Ltd. is facing a class action lawsuit filed in the District Court of New Jersey, alleging securities fraud by making misleading statements about the approval of their drug UGN-102. The lawsuit covers investors who acquired shares between July 27, 2023, and May 15, 2025. Investors are reminded of the upcoming deadline to join the class action, with necessary filings due by July 28, 2025. Bernstein Liebhard LLP is the law firm representing the affected shareholders, emphasizing their contingency fee structure for the representation.
Read more →URGN▲ +8.6%on this news· ran to +34% by day 3shared move
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA’s Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens Berman
UroGen Pharma Ltd. (URGN) is facing a securities class action lawsuit following a significant drop in share price after the FDA released a briefing document before an ODAC meeting. The lawsuit claims that UroGen misled investors regarding its communications with the FDA related to the new drug application for UGN-102, particularly about the trial design's adequacy. On May 21, 2025, the ODAC voted against the approval of UGN-102, raising concerns over the lack of a randomized trial. Investors are being urged to report their losses as the litigation progresses.
Read more →URGNUroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA’s Briefing Document and Subsequent ODAC Vote Against UGN-102 – Hagens Berman
UroGen Pharma Ltd. is facing a securities class action lawsuit following a significant drop in its stock price due to an adverse FDA briefing document regarding its drug application for UGN-102. The lawsuit claims that UroGen misled investors about the efficacy and support of its trial design in correspondence with the FDA. Additionally, the ODAC committee voted against UGN-102, citing concerns over the lack of a control arm in the trial, which casts doubt on the drug's benefits. Investors are being urged to submit their claims as the case unfolds.
Read more →URGNUROGEN PHARMA LTD. (NASDAQ: URGN) INVESTOR ALERT: Investors With Large Losses in UroGen Pharma Ltd. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
UroGen Pharma Ltd. is facing a securities class action lawsuit filed by investors who purchased shares between July 27, 2023, and May 15, 2025. The lawsuit alleges that the company made misrepresentations concerning the approval of its lead pipeline product, UGN-102. Investors are urged to act by filing papers to potentially serve as lead plaintiffs by July 28, 2025, though they may also remain absent class members. The law firm Bernstein Liebhard LLP is representing the plaintiffs on a contingency fee basis, indicating that shareholders will incur no fees or expenses.
Read more →URGNUROGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against UroGen Pharma Ltd. by Bragar Eagel & Squire, P.C. on behalf of investors who acquired UroGen securities from July 27, 2023, to May 15, 2025. The lawsuit alleges misleading statements about the effectiveness of UGN-102, UroGen's lead product for bladder cancer treatment, particularly concerning its clinical study design criticized by the FDA. Following the FDA's briefing and the unfavorable advisory committee vote, UroGen's stock experienced significant declines. Investors have until July 28, 2025, to apply for lead plaintiff status.
Read more →URGNUroGen Pharma Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses. July 28, 2025 Deadline to file Lead Plaintiff Motion.
UroGen Pharma Ltd. is facing significant challenges following the FDA's criticism of its New Drug Application for UGN-102, citing inadequacies in the submitted data. The company's stock saw a sharp decline after a briefing document raised concerns about interpreting efficacy results due to the absence of a concurrent control arm in the ENVISION trial. Further compounding these issues, the Oncologic Drugs Advisory Committee voted against the drug's approval, resulting in another significant drop in UroGen's stock price. Investors are being informed about a class action lawsuit with a deadline of July 28, 2025, to file a lead plaintiff motion.
Read more →URGN▼ -6.2%on this newsshared move
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA’s ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens Berman
UroGen Pharma Ltd. experienced a significant share drop of 44% following the FDA's Oncologic Drugs Advisory Committee (ODAC) voting against the risk-benefit profile of the company's therapy UGN-102. The therapy, aimed at treating low-grade non-muscle invasive bladder cancer, was deemed insufficiently supported by trial data. Concerns were specifically raised about the trial's single-arm design lacking a control group, which hampers a robust evaluation of the drug's effectiveness. An investigation by Hagens Berman has been initiated to assess potential misrepresentations by UroGen regarding its communications with the FDA.
Read more →URGNDeveloping Innovative Medicines to Treat Urothelial Cancers January 2025 Disclaimers This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act
UroGen is advancing innovative therapies for urothelial cancers, focusing on its technologies like RTGel to enhance treatment outcomes. The company’s JELMYTO has been FDA-approved for minimally invasive treatment of LG-UTUC and may set a new standard for non-musical invasive bladder cancer treatments. With a robust pipeline and substantial cash reserves, UroGen is positioned for sustainable growth; however, it faces regulatory uncertainties and potential challenges in clinical trial success.
Read more →URGNUroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 New Drug Application for UGN-102 accepted by US FDA; PDUFA target action date set for
UroGen Pharma has announced its Q3 2024 financial results, highlighting the FDA's acceptance of the New Drug Application for UGN-102, aimed at treating low-grade intermediate-risk non-muscle invasive bladder cancer. The company anticipates a potential FDA approval by June 2025, viewing UGN-102 as a possible game changer with a significant market opportunity. However, UroGen also reported a net loss of $23.7 million in the quarter and expects its JELMYTO revenues to fall short of previous guidance. The company remains focused on preparing for a successful commercial launch of UGN-102 if approved.
Read more →URGNUroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights Potential for an FDA decision as early as the first quarter of 2025, assuming p
UroGen Pharma is progressing ahead of schedule on its New Drug Application (NDA) submission for UGN-102, a potential treatment for low-grade intermediate-risk non-muscle invasive bladder cancer. The company released Q2 2024 financial results, showcasing strong revenues from its existing product JELMYTO, yet reported a net loss of $33.4 million. A promising ENVISION trial has indicated robust clinical efficacy, suggesting UGN-102 could reshape treatment options in its market. UroGen estimates a significant market opportunity, potentially catering to about 82,000 patients annually.
Read more →URGNUroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants PRINCETON, N.J. (BUSINESS WIRE)
UroGen Pharma has announced the commencement of an underwritten public offering to sell its ordinary shares and pre-funded warrants. The company is also granting underwriters a 30-day option to purchase an additional 15% of the offered shares. The offering is subject to market conditions and other factors, with no certainty regarding its completion or terms. UroGen specializes in treating urothelial and specialty cancers with its innovative RTGel technology.
Read more →URGN▲ +37.6%on this news· ran to +51% by day 1shared move
New Horizons in Bladder Cancer: UGN-102 Duration of Response Results from the ENVISION Study NASDAQ: URGN
UroGen announced promising results from the ENVISION study, highlighting the potential of UGN-102 to transform bladder cancer treatment, particularly for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The study's data, which originates from four clinical trials involving 593 patients, positions UGN-102 as a strong candidate for FDA approval, potentially marking it as the first treatment of its kind. However, risks remain, including the uncertainty surrounding NDA submissions and potential competition in the market. The total addressable market for UGN-102 is projected to exceed $5 billion, emphasizing its significant commercial potential.
Read more →URGNUroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights 12-month duration of response data from ENVISION study of UG
UroGen Pharma has reported its first quarter financial results for 2024, highlighting significant advancements in its product pipeline, especially UGN-102. The company is poised to announce 12-month duration of response data from the ENVISION study, which is expected to support its NDA submission. Additionally, UroGen continues to see growth in JELMYTO revenues, despite experiencing a net loss in the quarter. However, the company anticipates challenges from increased discounts related to Medicare refunds that may impact revenues this year.
Read more →URGN▼ -18%on this news
UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102 Initiated submission of a rolling NDA to the FDA for UGN-102; 12-month duratio
UroGen Pharma has reported significant growth in JELMYTO revenues alongside strategic developments for its investigational product UGN-102. The company is making progress on a rolling NDA submission for UGN-102, aimed at addressing low-grade intermediate-risk non-muscle invasive bladder cancer, with expectations to complete by September 2024. Despite the positive revenue trajectory, UroGen also faced setbacks with financial losses and increased operating costs. The revenue outlook for 2024 remains optimistic, targeting between $95 to $102 million from JELMYTO.
Read more →URGNDeveloping Innovative Medicines to Treat Urothelial Cancers March 2024 For investor audiences only. Not for promotional use with healthcare professionals. Forward-Looking Statements This investor presentation contains fo
UroGen is advancing its treatment pipeline for urothelial cancers, highlighting the FDA-approved JELMYTO and the promising UGN-102. The company aims to transform treatment for LG-IR-NMIBC, with a planned NDA submission for UGN-102 in 2024. Positive clinical results and a strong financial position bolster its future growth expectations, although challenges remain, particularly regarding clinical trial outcomes and regulatory approvals.
Read more →URGNDeveloping Innovative Medicines to Treat Urothelial Cancers February 2024 For investor audiences only. Not for promotional use with healthcare professionals. Forward-Looking Statements This investor presentation contains
UroGen is advancing its innovative medicines to treat urothelial cancers, revealing encouraging data regarding its treatments JELMYTO, UGN-102, and UGN-301. The company's proprietary RTGel technology aims to enhance existing therapies while promising significant growth in revenues and market penetration. UroGen plans to submit an NDA for UGN-102 in 2024, influenced by positive clinical trial results. However, the company faces several risks including regulatory hurdles and shifting prescriber behavior as they navigate the development and commercialization of these therapies.
Read more →URGNUroGen Pharma Reports Third Quarter 2023 Financial Results Continued strong growth with JELMYTO net product revenues of $20.9 million in Q3 2023; an increase of ~30% from the same period last year Agreement with United S
UroGen Pharma Ltd. reported impressive financial results for Q3 2023, with net product revenues from JELMYTO reaching $20.9 million, a significant increase of approximately 30% compared to the same period last year. The company highlighted positive results from their Phase 3 trials of UGN-102, leading to plans for a pre-NDA meeting with the FDA in 2024. Despite these achievements, UroGen reported a net loss of $21.9 million for the quarter, alongside ongoing research and administrative expenses. The company maintains confidence in achieving full-year net product revenues between $76 and $86 million.
Read more →URGNUroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments Both ENVISION and ATLAS Phase 3 trials of UGN-102 met primary endpoints in treating low-grade intermediate-risk non-muscle-invasive b
UroGen Pharma announced record sales of JELMYTO for the second quarter of 2023, totaling $21.1 million, alongside positive results from the ENVISION and ATLAS Phase 3 clinical trials for UGN-102, which met their primary endpoints. The developments position UGN-102 as a potentially transformative non-surgical treatment for patients with low-grade intermediate-risk non-muscle-invasive bladder cancer. However, the company reported a net loss of $24.1 million for the quarter and a decrease in cash reserves, raising concerns about financial stability despite the optimistic therapeutic prospects.
Read more →URGN▲ +98.6%on this news· ran to +151% by day 1
UroGen Announces $120 Million Private Placement of Ordinary Shares PRINCETON, N.J.
UroGen Pharma Ltd. has announced a private placement of ordinary shares, raising approximately $120 million. The funding is aimed at supporting both clinical and non-clinical development activities, as well as general corporate expenses. The private placement was led by major institutional investors, reflecting confidence in the company's strategies and product candidates. The closing of this placement is anticipated to occur by July 28, 2023, pending customary conditions.
Read more →URGN▲ +8%on this news
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments Reported JELMYTO Q1 2023 net product revenues of $17.2 million, an increase of ~27% from Q1 2022 Complete R
UroGen Pharma reported its financial results for the first quarter of 2023, achieving net product revenues of $17.2 million for JELMYTO, a 27% increase from the previous year. The company highlighted positive trends in sales growth and ongoing clinical trials for UGN-102, an investigational drug aimed at treating low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). However, UroGen also reported a net loss of $30.2 million for the quarter and increased interest expenses on long-term debt, indicating some financial challenges. The company remains optimistic as it prepares for key clinical trial results and potential new product applications.
Read more →URGNUroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments Reported JELMYTO full year 2022 net product revenues of $64.4 million, an increase of 34% from full ye
UroGen Pharma reported significant financial growth for 2022, highlighted by a 34% increase in net product revenues, totaling $64.4 million. The company's investigational drug, UGN-102, shows potential in transforming bladder cancer treatment and is moving toward New Drug Application submission following promising trial results. However, UroGen also faces challenges with a substantial net loss of $109.2 million and ongoing high operational costs. The firm is optimistic about future revenue growth and upcoming clinical data from its trials.
Read more →URGN▼ -16.3%on this news
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments Full enrollment of ENVISION Phase 3 pivotal trial with UGN-102 in low-grade intermediate-risk non-muscle invasive bladder cance
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments PRINCETON, N.J. November 10, 2022 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and special
Read more →URGN▼ -6.5%on this news
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments Reported Jelmyto net product revenue of $16.6 million, a 22% increase from the first quarter of 2022, and 28% increase YoY; re
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments PRINCETON, N.J. August 11, 2022 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialt
Read more →URGN▲ +6%on this news
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments Jelmyto net product revenue increased 81% over Q1 2021 to $13.6 million Enrollment of UGN-102 Phase 3 single-arm, ENVISION pivo
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments PRINCETON, N.J., May 10, 2022 - UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialt
Read more →URGNUroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments Jelmyto net product revenue increased 42% over Q3 2021 with $16.2 million in Q4 2021; full-year net product reve
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments PRINCETON, N.J., March 21, 2022 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urotheli
Read more →URGN▼ -22.9%on this news· ran to -35% by day 3
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments Shift to single-arm Phase 3 study for UGN-102 in bladder cancer streamlines pivotal study to form basis of FDA submission Jelmy
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments PRINCETON, N.J., November 15, 2021 UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and spe
Read more →URGNUroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments Strong Jelmyto net product revenue of $13.0 million for the second quarter of 202 1, representing more than 70% growth over th
UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate PRINCETON, N.J., August 4, 2021 UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic di
Read more →URGNUroGen Pharma Reports Strong Preliminary Jelmyto Sales for Second Quarter 2021 73% growth in net product revenue over 1Q 2021 to approximately $13.0 million in 2Q 2021 2Q 2021 operating expenses anticipated in the range
UroGen Pharma Reports Strong Preliminary Jelmyto Sales for Second Quarter 2021 PRINCETON, N.J. - July 14, 2021 UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dis
Read more →URGNUroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments Jelmyto net product revenue of $7.5 million for the first quarter of 202 1 New patient starts in March and April of 2021 increa
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments PRINCETON, N.J., May 13, 2021 - UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and
Read more →URGNUroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments RTW Investments, LP will provide UroGen with an upfront cash payment of $75 million and will receive tiered future payments based on worldw
UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments N.J., March 18, 2021 - UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, to
Read more →URGNUroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments Achieved Jelmyto net product revenue of $8.0 million for the fourth quarter of 2020; $11.8 million in first seve
UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate PRINCETON, N.J., March 18, 2021 UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers a
Read more →URGNForward Looking Statements This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential mark
UroGEN PHARMA J.P. MORGAN 2021 HEALTHCARE CONFERENCE JANUARY 11, 2021 Exhibit 99.1 Forward Looking Statements This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limi
Read more →URGNUroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments Top-line Results from UGN-102 OPTIMA II Phase 2b Trial Expected by Year End 2020; On Track to Initiate Phase 3 ATLAS Trial by Y
UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments Top-line Results from UGN-102 OPTIMA II Phase 2b Trial Expected by Year End 2020; On Track to Initiate Phase 3 ATLAS Trial by Year End Achieved Jelmyto Net Product Revenue of $3.5 Milli
Read more →URGNUroGen Pharma Announces Update on the Phase 2 Trial of an RTGel Hydrogel Formulation in Combination with BOTOX (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence Trial Did Not
UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel Hydrogel Formulation in Combination with BOTOX (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary PRINCETON, N.J., August 27, 2020 - UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceuti
Read more →URGNUroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments Received U.S. FDA Approval of Jelmyto , the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urot
UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments Received U.S. FDA Approval of Jelmyto , the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) Successfully Commenced Launch of J
Read more →URGNUroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments Completed Submission of New Drug Application (NDA) to U.S. FDA for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Ca
UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments Completed Submission of New Drug Application (NDA) to U.S. FDA for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Exclusive Worldwide License Agreement with
Read more →URGNUroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer UGN-101: Consistent Complete Response (CR) Rate of 59 Percent in
UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer Consistent Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) D
Read more →URGNUroGen Pharma Reports Second Quarter 2019 Financial Results and Recent Corporate Developments UGN-101 Rolling NDA Submission on Track for Q4 2019 with Planned Launch in 1H 2020 Final Topline UGN-101 Phase 3 Data from OLY
UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent Corporate Developments UGN-101 Rolling NDA Submission on Track for Q4 2019 with Planned Launch in 1H 2020 Final Topline UGN-101 Phase 3 Data from OLYMPUS Trial to be Announced in Q3 2019 Company Investor D
Read more →URGNUroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments Recent Data Presentation Highlights Consistent Complete Response Rate and Strong Durability at Six-Months in Evaluable Patients
UroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments Recent Data Presentation Highlights Consistent Complete Response Rate and Strong Durability at Six-Months in Evaluable Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
Read more →URGNUroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results On Track to Complete UGN-101 Rolling NDA Submission to the FDA in 2H 2019 Acceleration of Pre-Commercial Activities and Infrastructure Buildout
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results On Track to Complete UGN-101 Rolling NDA Submission to the FDA in 2H 2019 Acceleration of Pre-Commercial Activities and Infrastructure Buildout Underway to Support the Potential U.S. Approval and Launc
Read more →URGNUroGen Pharma Announces Pricing of Public Offering of Ordinary Shares NEW YORK (BUSINESS WIRE)
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares NEW YORK (BUSINESS WIRE) Jan. 23, 2019 UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-o
Read more →URGNUroGen Pharma Announces Proposed Public Offering of Ordinary Shares NEW YORK (BUSINESS WIRE)
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares NEW YORK (BUSINESS WIRE) January 22, 2019 UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-o
Read more →URGNUroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Data Demonstrates Complete Response
UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Data Demonstrates Complete Response (CR) Rate of 57 Percent in Patients with LG UTUC All Ev
Read more →URGNUROGEN PHARMA LTD. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) (Unaudited) September 30
CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) September 30, December 31, 2018 2017 Assets CURRENT ASSETS: Cash and cash equivalents $ 109,483 $ 36,999 Short-term investments - 36,001 Restri
Read more →URGNFDA Grants Breakthrough Therapy Designation (BTD) for UroGen Pharma s UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) UGN-101 Joins Select Group of Urologic Oncology Product C
FDA Grants Breakthrough Therapy Designation (BTD) for UroGen Pharma s UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) UGN-101 Joins Select Group of Urologic Oncology Product Candidates to Receive BTD On Track to Initiate Rolling Sub
Read more →URGNUROGEN PHARMA LTD. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) (Unaudited) June 30
CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) June 30, December 31, 2018 2017 Assets CURRENT ASSETS: Cash and cash equivalents $ 119,109 $ 36,999 Short-term investments - 36,001 Restricted
Read more →URGNUroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments
Plan to Initiate Q4 2018 Rolling New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for UGN-101, Ahead of Initial Projection of Q1 2019 Initiated Phase 2b Clinical Trial of UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bl
Read more →URGNUroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transitio
UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization RA A
Read more →URGNUroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report second quarter 2018 financial results on Tuesday, August 14, 2018, prior to the open of the
Read more →URGNUroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)
Company Expects to Begin U.S. Phase 2b Clinical Trial in Q3 2018 UGN-102 Has Potential to Become the First Front Line Non-Surgical Therapy for Patients with LG NMIBC RA’ANANA, Israel and NEW YORK, July 11, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-st
Read more →URGNUroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors Tomasello is a Renowned Industry Expert Responsible for the Commercialization of Revolutionary, Multi-Billion Dollar Products in Hematology-Oncology
UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors Tomasello is a Renowned Industry Expert Responsible for the Commercialization of Revolutionary, Multi-Billion Dollar Products in Hematology-Oncology Israel and NEW YORK, July 10, 2018 - UroGen Pharma Ltd. (
Read more →URGNUroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award
RA’ANANA, Israel and NEW YORK, June 13, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Arie Belldegrun,
Read more →URGNUroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance RA ANANA, Israel, and
UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance RA ANANA, Israel, and NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treat
Read more →URGNUroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference
RA’ANANA, Israel and NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, Chief
Read more →URGNUroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
Interim Results Showed Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade UTUC CRs to Date Remain Durable at Three, Six and Nine-Month Follow-Up RA’ANANA, Israel and NEW YORK, May 21, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage
Read more →URGNUroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments
Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA) Annual Meeting on May 21, 2018 Submission of UGN-101 New Drug Application (N
Read more →URGNUROGEN PHARMA LTD. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) (Unaudited) March 31
CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) March 31, December 31, 2018 2017 Assets CURRENT ASSETS: Cash and cash equivalents $ 127,460 $ 36,999 Short-term investments - 36,001 Restricted
Read more →URGNUroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2018 financial results on Tuesday, May 15, 2018, prior to the open of the marke
Read more →URGNUROGEN PHARMA LTD. 9 Ha Ta asiya Street, Ra anana 4365007, Israel
9 Ha Ta asiya Street, Ra anana 4365007, Israel You are cordially invited to attend the annual meeting (the Meeting ) of shareholders of UroGen Pharma Ltd. (the Company ) to be held on June 4, 2018 at 10:00 A.M., ET, at the offices of the Company at 499 Park Avenue, Suite 1200,
Read more →URGNUroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
RA’ANANA, Israel and NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that members of manag
Read more →URGNUroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel ) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC) RA ANANA, Israel, and
UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel ) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC) RA ANANA, Israel, and NEW YORK, April 3, 2018 UroGen Pharma Ltd. (Nasdaq:URGN), a clin
Read more →URGNUroGen Reports Fourth Quarter and Full Year 2017 Financial Results Presentation of MitoGel TM Interim Analysis from OLYMPUS Pivotal Trial in Patients with Low Grade Upper Tract Urothelial Cancer Planned at Upcoming Medic
UroGen Reports Fourth Quarter and Full Year 2017 Financial Results Presentation of MitoGelTM Interim Analysis from OLYMPUS Pivotal Trial in Patients with Grade Upper Tract Urothelial Cancer Planned at Upcoming Medical Meeting Conference Call to be Held Today at 8:30am ET Ra a
Read more →URGNUroGen Pharma to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 15, 2018
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report fourth quarter and full year 2017 financial results on Thursday, March 15, 2018, prior to t
Read more →URGNUroGen to Present at March 2018 Investor Conferences
RA’ANANA, Israel and NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that management plans to present at two investor conferences in March 2018: Cowen & Company 38th Annual Health Care Conference Oppenheimer 28th Annual Healthcare C
Read more →URGNUroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer Ra anana, Israel, and New York, NY
UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Ra anana, Israel, and New York, NY, February 14, 2018 - UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet nee
Read more →URGNUroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
RA’ANANA, Israel and NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the closing of its pub
Read more →URGNUroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
RA'ANANA, Israel and NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the pricing of its pub
Read more →URGNUroGen Pharma Announces Proposed Public Offering of Ordinary Shares
RA’ANANA, Israel and NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it filed a regist
Read more →URGNThis presentation and the accompanying oral presentation by UroGen Pharma Ltd. ("UroGen") contains forward-looking statements. All statements contained herein other than statements of historical fact constitute forward-l
Changing the Standard of Care for Urothelial Cancers January 2018 Exhibit 99.1 This presentation and the accompanying oral presentation by UroGen Pharma Ltd. ("UroGen") contains forward-looking statements. All statements contained herein other than statements of historical fac
Read more →URGNUroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer
Kate Bechtold, Also Formerly of Kite Pharma, to Join the Expanded Communications Team as Director of Corporate Communications & Investor Relations RA’ANANA, Israel, and NEW YORK, Jan. 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutic
Read more →URGNUroGen Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference
RA’ANANA, Israel and NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, the
Read more →URGNUroGen Pharma Expands Clinical Development Leadership Team Mark Schoenberg, M.D., Named Chief Medical Officer Elyse Seltzer, M.D., Appointed Senior Vice President of Clinical Development Ra anana, Israel, and New York, N
UroGen Pharma Expands Clinical Development Leadership Team Mark Schoenberg, M.D., Named Chief Medical Officer Elyse Seltzer, M.D., Appointed Senior Vice President of Clinical Development Ra anana, Israel, and New York, NY, December 12, 2017: UroGen Pharma Ltd. (NASDAQ:URGN), a
Read more →URGNUroGen Pharma Announces Oral Presentation at Society of Urologic Oncology (SUO) Annual Meeting
Principal Investigator Seth Lerner, M.D., to present design overview of ongoing Phase 3 OLYMPUS trial of MitoGel™ for the treatment of Low-Grade UTUC and data highlights from recently completed compassionate use program RA’ANANA, Israel and NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIR
Read more →URGNUROGEN PHARMA LTD. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) September 30, 2017 December 31, 2016 Assets CURRENT ASSETS: Cash and cash equivalents $ 79,171 $ 21,362 Restricted deposit 197 95 Accounts receivabl
Read more →URGNUroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Developments
RA’ANANA, Israel and NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced financial results for
Read more →URGNUroGen Pharma to Present at the Jefferies 2017 London Healthcare Conference
RA’ANANA, Israel and NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, the
Read more →URGNUroGen Pharma to Host Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017
RA’ANANA, Israel and NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that the Company will
Read more →URGNUroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel in Combination with BOTOX for the Treatment of Overactive Bladder Ra anana, Israel and New York, NY
UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel in Combination with BOTOX for the Treatment of Overactive Bladder Ra anana, Israel and New York, NY, November 6, 2017: UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutica
Read more →URGNUroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors Ra anana , Israel, and New York, NY
UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Ra anana, Israel, and New York, NY, November 2, 2017: UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs i
Read more →URGNUroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs
RA’ANANA, Israel, and NEW YORK, Oct. 26, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointments of J
Read more →URGNUroGen Pharma Strengthens Management Team with the Appointment of Paul Chu as Vice President of Business Development
RA'ANANA, Israel, and NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointment of P
Read more →URGNUroGen Pharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
RA'ANANA, Israel, and NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, th
Read more →URGNUroGen Pharma Receives FDA Fast Track Designation for MitoGel for the Treatment of Upper Tract Urothelial Carcinoma (UTUC) Ra anana, Israel, and New York, NY
UroGen Pharma Receives FDA Fast Track Designation for MitoGel for the Treatment of Upper Tract Urothelial Carcinoma (UTUC) Ra anana, Israel, and New York, NY, August 29, 2017: UroGen Pharma Ltd. (NASDAQ: URGN), a clinical-stage biopharmaceutical company developing treatments t
Read more →URGNUroGen Pharma Reports Second Quarter 2017 Financial Results and Recent Corporate Developments
Completed Initial Public Offering Raising $66.9 Million in Gross Proceeds Continuing Enrollment of Patients in the Phase 3 OLYMPUS Clinical Trial of MitoGel™ for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma RA’ANANA, Israel and NEW YORK, Aug. 14, 2017 (GLOBE NEWS
Read more →URGNInvestigational New Drug Application for RTGel TM in Combination with BOTOX for the Treatment of Overactive Bladder Submitted to FDA by Allergan RA ANANA, Israel, and
Investigational New Drug Application for RTGelTM in Combination with BOTOX for the Treatment of Overactive Bladder Submitted RA ANANA, Israel, and NEW YORK, July 19, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ: URGN), a clinical-stage biopharmaceutical company develop
Read more →URGNUroGen Pharma Ltd. (Nasdaq: URGN), to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, June 07, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, will visit the Nasdaq MarketSite in
Read more →URGNUroGen Pharma to Present at the Jefferies 2017 Global Healthcare Conference
RA’ANANA, Israel and NEW YORK, May 30, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced t
Read more →URGNUroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors Ra anana, Israel, New York, New York
UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors Ra anana, Israel, New York, New York, May 16, 2017: UroGen Pharma Ltd. (NASDAQ: URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field
Read more →URGNUroGen Pharma Announces Two Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association 2017 Annual Meeting
RA’ANANA, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today that the Compa
Read more →URGNUroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option
RA’ANANA, Israel and NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology with a focus on uro-oncology, announced today th
Read more →URGNUroGen Pharma Announces Pricing of Initial Public Offering
RA’ANANA, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the pricing of its initial p
Read more →URGNUroGen Pharma Welcomes New Board Member Kate Falberg
RA’ANANA, Israel, April 24, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company that is developing advanced non-surgical treatments to address unmet needs in the field of uro-oncology, announced today the appointment of Kathryn
Read more →URGNUroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma
RA’ANANA, Israel and NEW YORK, April 03, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a privately held, clinical-stage biopharmaceutical company that is developing advanced non-surgical treatments to address unmet needs in the field of uro-oncology, announced today that the first
Read more →URGNUroGen Pharma Announces FDA Acceptance of Investigational New Drug Application for MitoGel, a Novel Sustained Release Formulation of Mitomycin C, for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma
RA’ANANA, Israel and NEW YORK, Dec. 12, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company, today announced the acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for Mit
Read more →URGNUroGen Pharma Announces Agreement to License RTGel™ for Use with Neurotoxins to Allergan
RAANANA, Israel, Oct. 14, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma (“UroGen”), a privately-held, clinical-stage biotechnology company, announced today that it has completed an agreement to license worldwide rights to UroGen’s RTGelTM delivery system technology for use with neurotox
Read more →URGNUroGen Pharma Announces Three Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association’s 2016 Annual Meeting
NEW YORK and RA’ANANA, Israel, May 05, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma, a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology, announced today that the Company has
Read more →URGNUroGen Pharma Strengthens Board of Directors and Senior Management Team
NEW YORK and RA’ANANA, Israel, Feb. 09, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma, Ltd. a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology, announced today the appointment
Read more →URGNUroGen Pharma Strengthens Leadership Team and Expands Uro-Oncology Clinical Pipeline With Addition of TLR-7 Agonist Phase 2 Asset
NEW YORK and RA'ANANA, Israel, Jan. 13, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma, Ltd. (formerly known as TheraCoat), a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology,
Read more →Competitive Position
How URGN ranks across every disease it competes inCompetitive Position is a premium feature
See how URGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial